Anson Wurapa, MD
Infectious Disease · Decatur, GANPI 1871531442
Payments from drug & device makers
Across 463 payments — averaging $1601.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$381K
- Gilead$300K
- GSK$31K
- Roche Products Limited$26K
- Merck$513
- AbbVie$441
- plus $1K from 26 others
Across 27 payments — averaging $146.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
- Gilead$1K
- Viiv Healthcare Company$976
What the payments were for
- Consulting fees$8,23018%
- Speaking & faculty fees$30,65566%
- Travel & lodging$1,7414%
- Food & beverage$6,05513%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 121 | $381,361 |
| Gilead | 206 | $300,286 |
| GSK | 25 | $31,286 |
| Roche Products Limited | 8 | $26,166 |
| Merck | 23 | $513 |
| AbbVie(2 entities) | 17 | $441 |
| Insmed, Inc. | 6 | $211 |
| Janssen Scientific Affairs, LLC | 2 | $182 |
| Smith+Nephew | 8 | $147 |
| Tetraphase Pharmaceuticals, Inc. | 5 | $121 |
| Johnson & Johnson | 10 | $116 |
| Organogenesis Inc. | 4 | $88 |
| Aroa Biosurgery Incorporated | 3 | $80 |
| Paratek Pharmaceuticals, Inc. | 3 | $63 |
| Melinta Therapeutics, LLC | 3 | $53 |
| Kerecis Limited | 1 | $48 |
| Mylan Institutional Inc. | 2 | $46 |
| Shionogi Inc | 2 | $44 |
| Integra Lifesciences Corporation | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Mylan Specialty L.p. | 1 | $22 |
| Next Science LLC | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Vyera Pharmaceuticals, LLC | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $17 |
| Pfizer | 1 | $17 |
| Theratechnologies Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Reprise Biomedical, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$741,519 in reported general payments places this provider in the 95th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 188 | $821,693 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 95 | $369,681 |
| DovatoDolutegravir Sodium/Lamivudine | 75 | $249,676 |
| PrezcobixDarunavir/Cobicistat | 74 | $179,827 |
| CabenuvaCabotegravir/Rilpivirine | 20 | $144,007 |
| JulucaDolutegravir/Rilpivirine | 38 | $142,479 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 29 | $108,728 |
| TivicayDolutegravir Sodium | 49 | $108,564 |
| Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-50 | 13 | $77,351 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 11 | $60,143 |
| IsentressRaltegravir Potassium | 22 | $46,986 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 17 | $2,745 |
| CeftriaxoneCeftriaxone Sodium | 11 | $665 |
| Triamcinolone Acetonide | 21 | $461 |
| Doxycycline Monohydrate | 13 | $453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $300,286 | $1,191,374283 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Juluca, Tivicay | $381,361 | $644,726182 claims |
| Johnson & JohnsonPrezcobix | $116 | $179,82774 claims |
| MerckIsentress | $513 | $46,98622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Decatur
- Robin DretlerDecatur$1.8M
- Alexandra DretlerDecatur$203K
- Vincent MarconiDecatur$20K
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Harold KatnerMacon$1.3M
- Andrew DoldDacula$1.1M
- Jeffrey StephensMacon$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.